TERN
Terns Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.95
−0.03%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -9.1%
- EBIT
- -8.1%
- EPS
- +8.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -9.1%
- EBIT
- -8.1%
- Net income
- -8.3%
- EPS
- +8.0%
- Free cash flow
- -17.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025